title: [Intravesical instillation of trospium chloride, oxybutynin and verapamil for relaxation of the bladder detrusor muscle. A placebo controlled, randomized clinical test].
abstract: Therapy of detrusor hyperactivity with anticholinergic agents often is followed by adverse drug reactions. Intravesical application may be an interesting alternative. A randomised, single-blind, placebo-controlled, mono-centre clinical trial was carried out in 84 patients with urgency or urge incontinence. Due to intravesical administration of oxybutynin (CAS 5633-20-5) (n = 21) and trospium chloride (CAS 10405-02-4) (n = 21), respectively, a significant increase in maximum bladder capacity and decrease of detrusor pressure accompanied by an increase of residual urine were found in comparison to placebo in urodynamical investigations. Improvement of uninhibited bladder contractions occurred leading to higher filling volume. Under verapamil (CAS 152-11-4) (n = 21) no marked changes in the efficacy variables were found compared with placebo. All patients completed the study and were assessed with regard to efficacy and safety. No adverse events or marked changes in the vital signs were reported. The immediate onset of effect and the lack of adverse drug reactions suggest that treatment with topical oxybutynin or trospium chloride is an effective alternative in patients with intolerable side effects when orally treated. In addition, intravesical administration may be indicated in patients with bladder spasms due to indwelling catheter or in order to increase bladder capacity before percutaneous cystostomy.
authors.affiliation: Krankenhaus des Kreises Euskirchen, Urologische Abteilung, Mechernich.
authors.forename: G
authors.initials: G
authors.lastname: Fröhlich
authors.forename: S
authors.initials: S
authors.lastname: Burmeister
authors.forename: A
authors.initials: A
authors.lastname: Wiedemann
authors.forename: M
authors.initials: M
authors.lastname: Bulitta
mesh_terms: D000328:Adult; D001561:Benzilates; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007267:Injections; D008297:Male; D008333:Mandelic Acids / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D009126:Muscle Relaxation / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects*; D009662:Nortropanes / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D010276:Parasympatholytics / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D016037:Single-Blind Method; D001743:Urinary Bladder / Q000187:drug effects*; D014563:Urodynamics / Q000187:drug effects; D014700:Verapamil / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*
chemical_list: D001561:Benzilates; D002121:Calcium Channel Blockers; D008333:Mandelic Acids; D009662:Nortropanes; D010276:Parasympatholytics; C003330:trospium chloride; D014700:Verapamil; C005419:oxybutynin
vernacular_title: Intravesikale Instillation von Trospiumchlorid, Oxybutynin und Verapamil zur Relaxation des Harnblasen-Detrusors. Eine Plazebo-kontrollierte, randomisierte klinische Prüfung.